Decera Clinical Education Infectious Disease Podcast

In this episode, William R. Short, MD, MPH, AAHIVS, explores recommendations and data on switching to 2-drug single-tablet ART regimens.Listen as he gives his perspectives on:Indications for the available 2-drug single-tablet regimens: DTG/RPV and DTG/3TCThe SWORD-1 and SWORD-2 studies evaluating switching to DTG/RPV in virologically suppressed patientsReal-world experience with switching to DTG/RPV from the OPERA studyThe TANGO study evaluating switching to DTG/3TC from a stable TAF-based ART regimenThe SALSA study evaluating switching to DTG/3TC from any stable 3-drug ART regimenPresenter:William R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicinePerelman School of Medicine at the University of PennsylvaniaPhiladelphia, PennsylvaniaFollow along with the slides at:https://bit.ly/3n0Z8wUSee the entire program at:https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Gregory Dore, MBBS, PhD, FRACP, MPH, and Stacey Trooskin, MD, PhD, MPH, share lessons learned in the care of patients with HCV infection during the COVID-19 pandemic, including:TelehealthTreatment of PWIDTEMPO pilot studyMINMON studyPresenters:Gregory Dore, MBBS, PhD, FRACP, MPHProfessor, HeadViral Hepatitis Clinical Research ProgramKirby InstituteUniversity of New South WalesInfectious Diseases PhysicianSt. Vincent's HospitalSydney, AustraliaStacey Trooskin, MD, PhD, MPHChief Medical OfficerPhiladelphia FIGHT Community Health CentersFacultyDivision of Infectious DiseasesPerelman School of MedicineUniversity of PennsylvaniaPhiladelphia, PennsylvaniaFollow along with the slides at:https://bit.ly/3naBUVjLink to full program:https://bit.ly/3F5bxG8 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, hepatologist Giada Sebastiani, MD, discusses why the presence of obesity, metabolic syndrome, persistent elevation of ALT, or exposure to dideoxynucleoside analogues can trigger an evaluation for NAFLD and NASH, particularly in our aging population of patients with HIV with topics including:Metabolic factors HIV-related factorsWhich patients with HIV are at riskPresenter:Giada Sebastiani, MDAssociate Professor of MedicineMcGill University Health CentreDivision of Gastroenterology and Hepatology and Division of Infectious DiseasesClinician ScientistResearch Institute of McGill University Health CentreMontreal, Quebec, CanadaContent based on an online CME program supported by an educational grant from Theratechnologies Inc.Link to full program: https://bit.ly/3BYoXBP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode from the series “Key Decisions in HIV Care,” Milena Murray, PharmD, MSc, BCIDP, AAHIVP, and Jonah Musa, MBBS, MSCI, PhD, discuss important considerations for ART use in pregnancy, including DHHS and WHO guideline recommendations and data supporting recommended ART regimen options in pregnancy from IMPAACT 2010, Tsepamo, and DoLPHIN-2. They also discuss pharmacokinetic considerations and drug–drug interactions. Following their dialogue, the faculty field questions from healthcare professionals.Presenters:Milena Murray, PharmD, MSc, BCIDP, AAHIVPAssociate Professor Pharmacy PracticeMidwestern University College of Pharmacy, Downers Grove CampusDowners Grove, IllinoisHIV/ID Clinical PharmacistNorthwestern Memorial HospitalChicago, IllinoisJonah Musa, MBBS, MSCI, PhDProfessor, Obstetrics and GynecologyUniversity of JosHonorary Consultant Obstetrician and GynecologistJos University Teaching HospitalJos, NigeriaContent based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3GRxpGQLink to full program:https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Renslow Sherer, MD, discusses new COVID-19 data from IDWeek 2021, including:Prevention of COVID-19ChAdOx1 nCoV-19Ad26.COV2.STixagevimab plus cilgavimabOutpatients with COVID-19Remdesivir IVMolnupiravirHospitalized patients with COVID-19BaricitinibLenzilumabCasirivimab plus imdevimabLong-term COVID-19 outcomesSustained recoveryPresenter:Renslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisLink to full program and downloadable slides:https://bit.ly/3BCHF2E Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Oni Blackstock, MD, MHS, and Nina T. Harawa, PhD, MPH, discuss racial disparities in COVID-19 outcomes, including:Background on healthcare inequities among BIPOCCOVID-19 racial disparities and the healthcare inequities driving themOvercoming barriers to optimal COVID-19 care among BIPOCAddressing concerns about COVID-19 vaccination Motivational interviewing principles and the brief negotiated interview to earn trust and increase vaccine acceptancePresenters:Oni Blackstock, MD, MHSFounder and Executive DirectorHealth JusticeNew York, New YorkNina T. Harawa, PhD, MPHProfessor of Medicine and EpidemiologyUCLA David Geffen School of MedicineCharles R. Drew University of Medicine and SciencePolicy Core DirectorUCLA Center for HIV Identification, Prevention, and Treatment Services (CHIPTS)Los Angeles, CaliforniaLink to full program and downloadable slides:https://bit.ly/3blGA3R Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Nicholas Chamberlain, MD, provides an overview of the different antiretroviral drug formulations and dosing strategies in various stages of clinical development for long-acting HIV PrEP—advances that collectively offer the potential for highly individualized approaches to HIV biomedical prevention.Presenter:Nicholas Chamberlain, MDMedical DirectorAHF Healthcare Center – Atlanta MidtownDepartment of MedicineAIDS Healthcare FoundationAtlanta, GeorgiaContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program:https://bit.ly/3AFvsZY Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In episode 1 of an ongoing series of conversations between a physician and patient, Stacey Trooskin, MD, PhD, MPH, and patient advocate Brother Dan Palmer discuss approaches to improve access to HCV therapy. The conversation focuses on how barriers to care affected Dan’s health after his hepatitis C diagnosis and the strategies he employed to overcome them.Presenter:Stacey Trooskin, MD, PhD, MPH Chief Medical Officer Philadelphia FIGHT Community Health CentersFacultyDivision of Infectious DiseasesPerelman School of MedicineUniversity of PennsylvaniaPhiladelphia, PennsylvaniaContent based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences.Link to full program:https://bit.ly/3lSkSui Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Paul E. Sax, MD, and Renslow Sherer, MD, discuss the clinical significance of new data on the prevention and treatment of COVID-19, including:COVID-19 in immunocompromised hostsPrime-Boost Strategy for COVID-19 vaccinationCOVID-19 surge effectsMonoclonal antibody therapy for prevention and treatmentRemdesivir updateRepurposed drug, fluvoxamineWhat does the future of the pandemic look like?Presenters:Paul E. Sax, MDClinical DirectorHIV Program and Division of Infectious DiseasesBrigham and Women's HospitalProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsRenslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisLink to full program, including downloadable slidesets:https://bit.ly/3zVTwYW Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores recommendations and data to support the management of missed CAB plus RPV injections.Listen as she gives her perspectives on:Prescribing information recommendations for managing missed injections of CAB plus RPVPharmacokinetic modeling data to support management strategies for missed injectionsData from the ATLAS and FLAIR studies on missed injections and patient outcomesPresenter:Milena Murray, PharmD, MSc, BCIDP, AAHIVPAssociate ProfessorPharmacy PracticeMidwestern University College of PharmacyDowners Grove CampusDowners Grove, IllinoisHIV/ID Clinical PharmacistNorthwestern Memorial HospitalChicago, Illinois Follow along with the slides at: https://bit.ly/30nJfaZSee the entire program at: https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores recommendations and data on maternal weight gain associated with ART use in pregnancy.Listen as she gives her perspectives on:IMPAACT 2010 data on maternal weight gain with DTG + FTC/TAF vs DTG + FTC/TDF vs EFV/FTC/TDFSMARTT study data on gestational weight gain by ART classTsepamo Surveillance study data on maternal weight and birth outcomes among women receiving ART, as well as weight outcomes with DTG vs EFVDHHS Perinatal Guideline recommendations on dolutegravir and maternal weight gainPresenter:Milena Murray, PharmD, MSc, BCIDP, AAHIVPAssociate Professor Pharmacy PracticeMidwestern University College of PharmacyDowners Grove CampusHIV/ID Clinical PharmacistNorthwestern Memorial HospitalChicago, IllinoisFollow along with the slides at:https://bit.ly/3DusMQkSee the entire program at:https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Darcy Wooten, MD, discusses new HIV data from IDWeek 2021, including:A rapid test-and-treat program to start DTG/3TC in patients newly diagnosed with HIV (STAT)Efficacy when switching from 3-drug to 4-drug TAF-based regimens to DTG/3TC (TANGO)Virologic outcomes with 2-drug vs 3-drug ART regimens (Trio Health HIV Network Study)Metabolic complications in treatment-naive patients (Study 1489 and Study 1490)Resistance analysis of an investigational agent, lenacapavir (CALIBRATE)The Positive Perspectives Survey to evaluate the U=U Educational Campaign in North American patientsPresenter:Darcy Wooten, MDAssociate Professor of MedicineDivision of Infectious Diseases and Global Public HealthDepartment of MedicineUniversity of California, San DiegoSan Diego, CaliforniaLink to full program:https://bit.ly/3BCHF2E Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

During this episode, Lynora Saxinger, MD, FRCPC, CTropMed, updates listeners on the latest Emergency Use Authorizations and guideline recommendations for optimal clinical management of COVID-19. Gain practical insights on patient identification, risk stratification, and treatment.Key points include:Treatment of COVID-19 can be broken into antiviral and immune-modulating therapiesEach agent should be used at the correct disease stage to maximize benefitAntiviral medications and mAbs show the greatest promise early during COVID-19, before the host immune response is mountedPassive immunization with mAbs can prevent infection and severe disease—and mortality—if given early to hospitalized personsOperational challenges to using these medications exist, but given the epidemic of unvaccinated persons, these treatments become increasingly relevant to reduce burden on healthcare systemsPresenter:Lynora Saxinger, MD, FRCPC, CTropMedCochair, Scientific Advisory Group Alberta COVID-19 Emergency Coordination Centre Associate ProfessorDivision of Infectious DiseasesDepartment of Medicine University of AlbertaEdmonton, Alberta, CanadaContent based on an online CME program supported by an educational grant from Gilead Sciences, Inc.Follow along with the slides at:https://bit.ly/3BxQKtD Link to full program:https://bit.ly/3BwzdlC Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode from the series “Key Decisions in HIV Care,” Jason Halperin, MD, MPH, and Jürgen K. Rockstroh, MD, discuss important considerations in the rapid initiation of ART, including guideline recommendations and data supporting recommended ART regimen options for rapid initiation and emerging data for the 2-drug regimen dolutegravir/lamivudine for rapid start from the STAT study. Following their dialogue, the faculty field questions from healthcare professionals.Presenters:Jason Halperin, MD, MPHAssistant Professor of MedicineDepartment of Infectious DiseasesTulane UniversityInfectious Disease PhysicianCrescentCareNew Orleans, LouisianaJürgen K. Rockstroh, MDProfessor of MedicineUniversity Hospital BonnDepartment of Medicine IBonn, Germany Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at: https://bit.ly/2XWPuBiLink to full program: https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores the data to support the use of tenofovir alafenamide in pregnancy.Listen as she gives her perspectives on:DHHS guideline recommendations for the use of TAF in pregnancyPharmacokinetic data to support adequate TAF concentrations throughout pregnancyAvailable antiretroviral pregnancy registry information on the use of TAF in pregnancyData from the IMPAACT 2010 study to support the use of a TAF-containing regimen in pregnancyPresenter:Milena Murray, PharmD, MSc, BCIDP, AAHIVPAssociate Professor Pharmacy PracticeMidwestern University College of PharmacyDowners Grove CampusHIV/ID Clinical PharmacistNorthwestern Memorial HospitalChicago, Illinois Follow along with the slides at:https://bit.ly/3ofTHLrLink to full program: https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Tracy Zivin-Tutela, MD, discusses factors that put your patients at risk for shingles and its complications.Tracy Zivin-Tutela, MDInfectious Diseases SpecialistDepartment of Infectious DiseasesFountain Valley Regional HospitalLos Alamitos Medical CenterFountain Valley, CaliforniaUsing a case study and the latest data, this podcast covers topics such as: Pathophysiology and epidemiologyDisease burden and potential complications in older patients, including postherpetic neuralgiaRisk factors, including age, immunosenescence, chronic diseases, unvaccinated statusContent based on a CME program supported by an educational grant from GlaxoSmithKlineFollow along with the downloadable slides at:https://bit.ly/3ENbcbPLink to full program:https://bit.ly/3o4PB8N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jason Halperin, MD, MPH, explores the data to support rapid ART initiation in patients with OUD.Listen as he gives his perspectives on:DHHS guidelines for rapid initiation of ART and specific recommendations for patients with substance use disordersSAMSHA recommendations for the treatment of OUDMedications that are recommended for the treatment of OUD, including drug–drug interaction considerations with ARTData to support the treatment of OUD to improve HIV viral suppression ratesIn addition, hear his patient’s perspective on the importance of receiving treatment for his OUD and HIV together. Presenter:Jason Halperin, MD, MPHAssistant Professor of MedicineDepartment of Infectious DiseasesTulane UniversityInfectious Disease PhysicianCrescentCareNew Orleans, Louisiana Follow along with the slides:https://bit.ly/3kE5WzqSee the entire program at:https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jason Halperin, MD, MPH, explores the data to support rapid ART initiation in adolescent patients.Listen as he gives his perspectives on:DHHS and IAS-USA guidelines for rapid initiation and specific recommendations for adolescents and young adultsCrescentCare data comparing the virologic outcomes for patients 18-24 years of age compared with those aged 25 years or olderData to suggest that rapid ART upholds equityIn addition, hear his patient’s perspective on the importance of rapid initiation of ART to prevent transmission to others and the burden it lifted for him.Presenter:Jason Halperin, MD, MPHAssistant Professor of MedicineDepartment of Infectious DiseasesTulane UniversityInfectious Disease PhysicianCrescentCareNew Orleans, Louisiana Follow along with the slides at:https://bit.ly/39xL5r0See the entire program at:https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Colleen Kelley, MD, MPH, discusseskey features and available safety and efficacy data on investigational long-acting HIV pre-exposure prophylaxis strategies that are in late stages of clinical development.Presenter:Colleen Kelley, MD, MPHAtlanta, Georgia Colleen Kelley, MD, MPH, has disclosed that she has received funds for research support from Gilead Sciences, Moderna, Novavax, and ViiV Healthcare. Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program: https://bit.ly/3AFvsZY Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this second of 2 episodes, Shobha Swaminathan, MD, and Eric S. Daar, MD, review key data influencing their practice following the IAS 2021 Conference, including data on investigational antiretroviral agents, lenacapavir and islatravir, and alternative dosing of BPaL for MDR-TB. This episode includes discussion of:An extension of FLAIR, demonstrating virologic efficacy and safety of long-acting CAB plus RPV at Week 124A Week 26 safety and efficacy analysis of CAPELLA, a study of lenacapavir in heavily treatment–experienced PWHCALIBRATE, a study of the safety and efficacy of lenacapavir in treatment-naive PWHA Week 96 safety analysis of Protocol 011, evaluating islatravir plus DOR in treatment-naive patientsA Week 24 safety and pharmacokinetic analysis of Protocol 016, evaluating oral islatravir once monthly for PrEPZeNix, a phase III trial of pretomanid, bedaquiline, and linezolid (BPaL) in patients with highly resistant TBPresenters:Eric S. Daar, MDChief, Division of HIV MedicineHarbor-UCLA Medical CenterProfessor of MedicineDavid Geffen School of Medicine at UCLALos Angeles, CaliforniaShobha Swaminathan, MDAssociate ProfessorDivision of Infectious Diseases Department of MedicineRutgers New Jersey Medical SchoolNewark, New JerseyFollow along with the slides at:https://bit.ly/3hvRN5bContent based on an online CME program supported by an educational grant from ViiV Healthcare. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, and Arthur Kim, MD, discuss data on the potential use of monoclonal antibodies (mAb) for the prevention and treatment of COVID-19, including:Rationale for use of mAbPotential for resistance to mAbSingle vs combination therapy with mAbChallenges in implementation of mAb as treatment or preventionBamlanivimabSotrovimabCasirivimab plus imdevimabLink to full program, including downloadable slidesets: https://bit.ly/3zVTwYWPresenters: Sharon R. Lewin, AO, FRACP, PhD, FAHMSDirector, The Peter Doherty Institute for Infection and ImmunityProfessor of Infectious DiseasesFaculty Medicine Dentistry and Health SciencesUniversity of Melbourne and Royal Melbourne HospitalConsultant Infectious Diseases PhysicianDepartment of Infectious DiseasesRoyal Melbourne Hospital and Alfred HospitalMelbourne, AustraliaArthur Kim, MDAssociate ProfessorDepartment of MedicineHarvard Medical SchoolDirector, Viral Hepatitis ClinicDivision of Infectious DiseasesMassachusetts General HospitalBoston, MassachusettsSharon R. Lewin, AO, FRACP, PhD, FAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; funds for research support from Leidos; and other financial or material support from Gilead Sciences, Merck, and ViiV Healthcare.Arthur Kim, MD, has disclosed that he has served on the drug and safety monitoring board for Kintor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this first of 2 episodes, Shobha Swaminathan, MD, and Eric S. Daar, MD, review key data influencing their practice following the IAS 2021 Conference, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB plus RPV for ART in treatment-naive PWH. This episode includes discussion of:A Global Clinical Platform that evaluated outcomes of PWH hospitalized with COVID-19A post hoc analysis of TANGO, evaluating the virologic and metabolic outcomes when switching to DTG/3TC vs continued 3- or 4-drug TAF-based regimensA Week 48 analysis of SALSA, demonstrating virologic efficacy and favorable safety profile of switching to DTG/3TC vs continuing a 3-drug ART regimenPresenters:Eric S. Daar, MDChief, Division of HIV MedicineHarbor-UCLA Medical CenterProfessor of MedicineDavid Geffen School of Medicine at UCLALos Angeles, CaliforniaShobha Swaminathan, MDAssociate ProfessorDivision of Infectious Diseases Department of MedicineRutgers New Jersey Medical SchoolNewark, New JerseyFollow along with the slides at:https://bit.ly/3hvRN5bContent based on an online CME program supported by an educational grant from ViiV Healthcare. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this series of 3 episodes, Geeta Gupta, MD, discusses strategies for optimizing ART in heavily treatment–experienced patients with HIV, including management of virologic failure and switching ART in virologically suppressed patients with underlying resistance. The 3 episodes will include analyses from:BENCHMRK, which demonstrated that the number of active drugs predicts outcomes in treatment-experienced patientsTMB-301, a study that added the monoclonal antibody ibalizumab in pretreated patients with multidrug-resistant HIV and demonstrated significant decreases in HIV-1 RNABRIGHTE, which showed that the addition of fostemsavir in heavily treatment–experienced patients with HIV led to a significant decrease in HIV-1 RNAVIKING-3, a study that demonstrated the addition of DTG dosed BID in INI-resistant patients was effective in decreasing HIV-1 RNASWITCHMRK, a study that showed underlying resistance matters when deciding to switch regimens in a treatment-experienced, virologically suppressed patient, especially when switching to a regimen with a low barrier to resistanceDAWNING, a study that demonstrated that DTG, when added to 2 NRTIs, was superior to RTV-boosted LPV in patients with virologic failure on an NNRTI plus 2 NRTIsBRAAVE, which evaluated safety and efficacy of switching to BIC/FTC/TAF in Black patients virologically suppressed on 2 NRTIs plus a third agentIn addition, Dr. Gupta reviews current DHHS ART guideline recommendations related to managing virologic failure, including drug resistance testing and drug selection, as well as switching recommendations in patients with viral suppression and underlying drug resistance.Presenter:Geeta Gupta, MDProfessorDirector, AIDS Education and Training CenterUniversity of California, IrvineOrange, CaliforniaFollow along with the slides at:https://bit.ly/3zxKBfLContent based on an online CME program supported by an educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3ux6FF8 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Mindie H. Nguyen, MD, MAS, AGAF, FAASLD, and Lewis R. Roberts, MB ChB, PhD, examine the HBV burden and care disparities in specific populations, including Asian Americans and foreign-born immigrants, and strategies to address barriers to care.Presenters:Mindie H. Nguyen, MD, MAS, AGAF, FAASLDProfessor of MedicineDepartment of Gastroenterology and HepatologyStanford University Medical CenterPalo Alto, CaliforniaLewis R. Roberts, MB ChB, PhDProfessor of Medicine and ConsultantDivision of Gastroenterology and HepatologyMayo ClinicRochester, MinnesotaContent based on a CME program supported by educational grants provided by AbbVie; Gilead Sciences, Inc.; and Janssen Therapeutics, Division of Janssen Products, LP To follow along, download the slides at: https://bit.ly/3gWStjZLink to full program:https://bit.ly/3kKIb9a Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this series of 3 episodes, Geeta Gupta, MD, discusses strategies for optimizing ART in heavily treatment–experienced patients with HIV, including management of virologic failure and switching ART in virologically suppressed patients with underlying resistance. The 3 episodes will include analyses from:BENCHMRK, which demonstrated that the number of active drugs predicts outcomes in treatment-experienced patientsTMB-301, a study that added the monoclonal antibody ibalizumab in pretreated patients with multidrug-resistant HIV and demonstrated significant decreases in HIV-1 RNA BRIGHTE, which showed that the addition of fostemsavir in heavily treatment–experienced patients with HIV led to a significant decrease in HIV-1 RNA VIKING-3, a study that demonstrated the addition of DTG dosed BID in INI-resistant patients was effective in decreasing HIV-1 RNASWITCHMRK, a study that showed underlying resistance matters when deciding to switch regimens in a treatment-experienced, virologically suppressed patient, especially when switching to a regimen with a low barrier to resistanceDAWNING, a study that demonstrated that DTG, when added to 2 NRTIs, was superior to RTV-boosted LPV in patients with virologic failure on an NNRTI plus 2 NRTIsBRAAVE, which evaluated safety and efficacy of switching to BIC/FTC/TAF in Black patients virologically suppressed on 2 NRTIs plus a third agentIn addition, Dr. Gupta reviews current DHHS ART guideline recommendations related to managing virologic failure, including drug resistance testing and drug selection, as well as switching recommendations in patients with viral suppression and underlying drug resistance.Presenter:Geeta Gupta, MDProfessorDirector, AIDS Education and Training CenterUniversity of California, IrvineOrange, CaliforniaFollow along with the slides at:https://bit.ly/3zxKBfLContent based on an online CME program supported by an educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3ux6FF8 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this series of 3 episodes, Geeta Gupta, MD, discusses strategies for optimizing ART in heavily treatment–experienced patients with HIV, including management of virologic failure and switching ART in virologically suppressed patients with underlying resistance. The 3 episodes will include analyses from:BENCHMRK, which demonstrated that the number of active drugs predicts outcomes in treatment-experienced patientsTMB-301, a study that added the monoclonal antibody ibalizumab in pretreated patients with multidrug-resistant HIV and demonstrated significant decreases in HIV-1 RNABRIGHTE, which showed that the addition of fostemsavir in heavily treatment–experienced patients with HIV led to a significant decrease in HIV-1 RNA VIKING-3, a study that demonstrated the addition of DTG dosed BID in INI-resistant patients was effective in decreasing HIV-1 RNASWITCHMRK, a study that showed underlying resistance matters when deciding to switch regimens in a treatment-experienced, virologically suppressed patient, especially when switching to a regimen with a low barrier to resistanceDAWNING, a study that demonstrated that DTG, when added to 2 NRTIs, was superior to RTV-boosted LPV in patients with virologic failure on an NNRTI plus 2 NRTIsBRAAVE, which evaluated safety and efficacy of switching to BIC/FTC/TAF in Black patients virologically suppressed on 2 NRTIs plus a third agentIn addition, Dr. Gupta reviews current DHHS ART guideline recommendations related to managing virologic failure, including drug resistance testing and drug selection, as well as switching recommendations in patients with viral suppression and underlying drug resistance.Presenter:Geeta Gupta, MDProfessorDirector, AIDS Education and Training CenterUniversity of California, IrvineOrange, CaliforniaFollow along with the slides at:https://bit.ly/3zxKBfLContent based on an online CME program supported by an educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3ux6FF8 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Joseph J. Eron, Jr., MD, explores whether weight gain should or should not be a factor in determining initial therapy.Listen as he gives his perspectives on:Weight gain following ART initiation by ARV class and ARV drugResults of the ADVANCE and GEMINI-1 and -2 studies, with exploration of weight, risk of CVD and diabetesBMI changes in PWHDHHS and IAS-USA guidelines for initial therapyPresenter:Joseph J. Eron, MDProfessor of Medicine and EpidemiologyUniversity of North Carolina School of MedicineDirector, AIDS Clinical Trials UnitUniversity of North CarolinaChapel Hill, North CarolinaFollow along with the slides at:https://bit.ly/3DyLgA3See the entire program at:https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, David Malebranche, MD, MPH, discusses modifying ART in virologically suppressed patients, including switching ART in a patient with daily pill fatigue, switching ART to avoid comorbidities and simplifying ART in the context of known multidrug resistance. The overview will include analyses from:The ATLAS and FLAIR studies in which long-acting intramuscular CAB + RPV was initiated after initial virologic suppression with oral therapyD:A:D study data that found cumulative use of RTV-boosted DRV, but not RTV-boosted ATV, was independently associated with a small but progressively increasing risk of CVD eventsThe SWORD-1 and -2 evaluating the switch to DTG + RPV vs continuation of baseline ART in virologically suppressed adultsThe TANGO study that compared switching to DTG/3TC vs continuing a TAF-based 3-drug regimenThe DAWNING study that showed favorable outcomes for treatment-experienced patients switched to DTG containing regimens with an M184V mutation, whether the regimen contained emtricitabine or lamivudine or notStudy 380-4030 that showed noninferiority in maintenance of viral suppression when switching to BIC/FTC/TAF from DTG + FTC/(TAF or TDF)BRAAVE 2020 that evaluated the impact of baseline resistance on outcomes following a switch to BIC/FTC/TAF in Black PWHIn addition, Dr. Malebranche reviews current recommendations by the DHHS regarding considerations when switching regimens in virologically suppressed patients and switching regimens in patients with viral suppression and drug resistance.Presenter:David J. Malebranche, MD, MPHInternal Medicine PhysicianHIV/Sexual Health SpecialistClinician, AIDS Healthcare Foundation (AHF) Medical ClinicAtlanta, GeorgiaFollow along with the slides at:https://bit.ly/3kseOqkContent based on an online CME program supported by an educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3ux6FF8 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Paul E. Sax, MD, discusses emerging drug therapies and treatment options for patients with HIV, including rapid initiation of ART, long-acting ART, and 2-drug ART regimens. The overview will include analyses from:The RAPID ART program in San Francisco, where same-day initiation of ART led to faster HIV-1 RNA suppression that was maintained at greater than 92% during a 3-year periodThe DIAMOND study analyzing virologic efficacy and safety at 48 weeks after initiating DRV/COBI/FTC/TAF within 24 hours of HIV infection diagnosisA rapid ART start program in young PWH in New Orleans that demonstrated achievement of viral suppression in fewer than 30 days and no discontinuations due to adverse eventsThe ATLAS (including ATLAS-2M) and FLAIR studies that demonstrated efficacy and safety of long-acting injectable CAB plus RPVSWORD-1 and SWORD-2 that demonstrated switching to a 2-drug regimen of DTG plus RPV in virologically suppressed adults was safe and effectiveGEMINI-1 and GEMINI-2 that demonstrated noninferiority of DTG plus 3TC compared with DTG plus FTC/TDFTANGO that demonstrated safety and efficacy of switching to DTG/3TC in virologically suppressed adults receiving a TAF-based regimenIn addition, Dr. Sax reviews current recommendations by the DHHS, WHO, and IAS-USA regarding these emerging therapies and treatment paradigms. Presenter:Paul E. Sax, MDClinical DirectorHIV Program and Division of Infectious DiseasesBrigham and Women’s HospitalProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsFollow along with the slides at:https://bit.ly/3zdPwm2 Content based on an online CME program supported by an educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3ux6FF8 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jennifer Cocohoba, PharmD, and Jason Schafer, PharmD, MPH, discuss key studies from IAS 2021 that will influence the role of the pharmacist in the treatment and prevention of HIV. Their discussion includes analyses of:The 144-week analysis of the TANGO study, showing high rates of virologic suppression of patients switched from a TAF-containing regimen to DTG plus 3TCThe 144-week analysis of the TANGO study, showing high rates of virologic suppression of patients switched from a TAF-containing regimen to DTG plus 3TCAn extension of the FLAIR study, evaluating efficacy and safety of long-acting CAB plus RPV in treatment-naive patientsThe CUSTOMIZE study, an implementation effectiveness study that evaluated the feasibility of implementing provision of long-acting CAB plus RPV in the clinic settingThe HPTN 084 study of PrEP using CAB vs TDF plus FTC in sexually active cisgender womenThe CALIBRATE and CAPELLA studies of long-acting lenacapavir in treatment-naive and treatment-experienced patients, respectivelyIn addition, Drs. Cocohoba and Schafer discuss key considerations of these medications, including cost and acquisition logistics.Presenters:Jennifer Cocohoba, PharmDProfessorDepartment of Clinical PharmacyUniversity of California, San FranciscoSan Francisco, CaliforniaJason Schafer, PharmDProfessor and Vice ChairJefferson College of PharmacyThomas Jefferson UniversityPhiladelphia, PennsylvaniaContent based on conference coverage of IAS 2021 with educational rant support from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp.; and ViiV Healthcare.Link to full program:https://bit.ly/3z8SBnC Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Babafemi Taiwo, MBBS, discusses new HIV data from IAS 2021, including:WHO Global Clinical Platform: COVID-19 outcomes in PWH2-drug regimen of DTG/3TC: efficacy, metabolic outcomes (TANGO)Investigational antiretroviral useCAB LA + RPV LA in treatment-naive PWH (FLAIR)Investigational antiretroviral agentsLEN (CAPELLA, CALIBRATE)ISL (P011, P016)Alternative BPaL dosing in treatment of drug-resistant TB (ZeNix)Babafemi Taiwo, MBBSGene Stollerman Professor of MedicineChief, Division of Infectious DiseasesNorthwestern University Feinberg School of MedicineChicago, IllinoisContent based on a CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP.; Merck Sharp & Dohme Corp; and ViiV Healthcare.Follow along with an expanded slideset at: https://bit.ly/3syWD5TLink to full program: https://bit.ly/3z8SBnC Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

During this episode, Darrell H. S. Tan, MD, FRCPC, PhD, discusses approved and guideline-recommended oral HIV PrEP regimens and provides key insights on determining PrEP candidacy as well as important considerations for specific populations/clinical scenarios, including adolescents, pregnancy/breastfeeding, and transgender individuals.Presenter:Darrell H. S. Tan, MD, FRCPC, PhDAssociate Professor Division of Infectious DiseasesUniversity of TorontoClinician-ScientistDivision of Infectious DiseasesSt. Michael’s HospitalToronto, CanadaContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program: https://bit.ly/3AFvsZY Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In episode 5 of an ongoing series of sharing sessions between a physician and patient, Anna Christina L. dela Cruz, MD, and Rhonda, who is living with chronic hepatitis B, discuss what to do when the decision to start treatment is not clear because of borderline ALT test results and HBV DNA levels. Their conversation highlights a need for patient education and shared decision-making.Presenter:Anna Christina L. dela Cruz, MDAssociate ProfessorDivision of Digestive Diseases and NutritionDepartment of Internal MedicineUniversity of KentuckyLexington, KentuckyContent based on an online CME program supported by an independent educational grant from Gilead Sciences.Link to full program:https://bit.ly/3u196yK Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In episode 4 of an ongoing series of sharing sessions between a physician and patient, Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, discusses hepatitis B diagnosis and treatment with his patient, Mark. The conversation focuses on Mark’s missed HBV diagnosis and likely reactivation following treatment for rheumatoid arthritis and raises awareness for needed improvements to communication between multidisciplinary healthcare teams. Presenter:Geoffrey M. Dusheiko MD, FCP(SA), FRCPEmeritus Professor of MedicineUniversity College London School of Medicine Kings College HospitalLondon, United Kingdom Content based on an online CME program supported by an independent educational grant from Gilead Sciences.Link to full program:https://bit.ly/3u196yK Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Oluwaseun Falade-Nwulia, MBBS, MPH, and Joseph K. Lim, MD, examine the HCV burden and care disparities in specific populations, including Black, Hispanic, Asian, American Indian, and Alaska Native persons, and strategies to address barriers to care.Oluwaseun Falade-Nwulia, MBBS, MPHAssociate ProfessorDivision of Infectious DiseasesJohns Hopkins University School of MedicineAttendingDivision of Infectious DiseasesJohns Hopkins HospitalBaltimore, MarylandJoseph K. Lim, MDProfessor of MedicineDirector, Clinical HepatologyVice-ChiefSection of Digestive DiseasesYale University School of MedicineNew Haven, ConnecticutContent based on a CME program supported by educational grants provided by AbbVie, Gilead Sciences, Inc., and Janssen Therapeutics, Division of Janssen Products, LP To follow along, download the slides at:https://bit.ly/36UDLViLink to full program:https://bit.ly/3kKIb9a Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Stefan Zeuzem, MD, discusses exciting new data on viral hepatitis reported at the virtual EASL 2021, including new findings on treatment of HDV, treatment of HBV and HCV in children, linking patients to care, and new molecules being investigated for HBV cure.Stefan Zeuzem, MDProfessor of MedicineChief, Department of Medicine IJW Goethe University Hospital Frankfurt, GermanyContent based on a CME program supported by educational grants provided by AbbVie, Antios Therapeutics, and Gilead Sciences, Inc.To follow along, download the slides at:https://bit.ly/3rl8AeSLink to full program:https://bit.ly/3ky46QK Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode,Drs Elizabeth Bukusi, Peter Godfrey-Faussett, and Nina Russell discuss promising advances in the field of HIV vaccine research and how we can prepare for optimal rollout of an eventual HIV vaccine. Presenters:Elizabeth Anne Bukusi, MBChB, M.Med (ObGyn), MPH, PhD , PGD (Research Ethics), MBE (Research Ethics), CIPSenior Principal Clinical Research ScientistCenter for Microbiology ResearchKEMRIResearch ProfessorDepartments of Global Health and Obstetrics and GynecologyUniversity of Washington,Nairobi, KenyaSeattle, WashingtonPeter Godfrey-Faussett, MBBS, FRCP(UK)Science AdvisorUnited Nations Joint Programme on HIV (UNAIDS)Professor of Infectious Diseases and International HealthLondon School of Hygiene and Tropical MedicineLondon, United KingdomNina Russell, MDDirector for TB and HIV PreventionBill & Melinda Gates FoundationSeattle, WashingtonLink to full series: https://bit.ly/2UgrQ12Link to the HIV unmuted series from IAS: https://hivunmuted.iasociety.org/Content is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast, Spencer H. Durham, PharmD, BCPS, BCIDP; Stefan Gravenstein, MD, MPH; and Barbara Resnick, PhD, CRNP, discuss risk factors for respiratory syncytial virus among adults, the need for a vaccination strategy in this population, and the evolving clinical studies on vaccines for older adults. Following their dialogue, the faculty field questions from healthcare professionals.Presenters:Spencer H. Durham, PharmD, BCPS, BCIDP Associate Clinical Professor of Pharmacy Practice Director, Alumni & Professional Affairs Clinical Affairs & Outreach Auburn University Harrison School of Pharmacy Auburn, AlabamaStefan Gravenstein, MD, MPHDirectorDivision of Geriatrics and Palliative MedicineThe Warren Alpert Medical School of Brown UniversityProvidence, Rhode IslandBarbara Resnick, PhD, CRNPProfessorSchool of NursingUniversity of MarylandNurse PractitionerRoland Park PlaceBaltimore, MarylandContent based on an online CME program supported by educational grants from Janssen Therapeutics, Division of Janssen Products, LP.Link to full program:https://bit.ly/3kvr8ro Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode, Dr. Swati Gupta and Mr. Marc Dixneuf discuss how to broaden global advocacy and increase investment for an HIV vaccine.Presenters:Swati Gupta, DrPH, MPHVice President and Head of Emerging Infectious Diseases and Scientific StrategyInternational AIDS Vaccine InitiativeNew York, New YorkMarc Dixneuf, PhDDirector GeneralAIDESPantin, FranceSpecial Commentator: Jonathan Weber, MB, BChir, PhD, FRCP, FRCPath, FMed SciDean of the Faculty of MedicineImperial CollegeLondon, United KingdomLink to full series:https://bit.ly/3ytytMYLink to the HIV unmuted series from IAS:https://bit.ly/3f5qC0dContent is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jehan Budak, MD, discusses the use of HIV-ASSIST, a free, online, decision-support tool to inform ART selection.Jehan Budak, MDAssistant ProfessorDivision of Allergy & Infectious DiseasesUniversity of WashingtonSeattle, WashingtonContent based on a CME program supported by educational grants from Gilead Sciences, Inc.; Theratechnologies; and ViiV Healthcare.Link to full program:https://bit.ly/33RZ9Zy Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Latesha Elopre, MD, MSPH, explains how to initiate pre-exposure prophylaxis (PrEP), including in underserved communities, with examples on overcoming barriers and improving access.Listen as she gives her perspectives on:Evidence for PrEP efficacy in the DISCOVER studyRecommendations in MSM, heterosexual men and women, injection drug users, and adolescents and adults weighing more than 77 lbCDC guidanceHow PrEP is underused, including racial/ethnic disparitiesStrategies to overcoming barriersPresenter:Latesha Elopre, MD, MSPHAssistant ProfessorDivision of Infectious DiseasesDirector of Diversity and InclusionGeneral Medical EducationUniversity of Alabama at BirminghamBirmingham, AlabamaFollow along with the slides at:https://bit.ly/3ABCNL8See the entire program at:https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Daniel J. Kuritzkes, MD, reviews key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure. The overview will include analyses of:ATLAS and FLAIR studies of long-acting injectable CAB + RPVATLAS 2M dosing studyFDA approval and DHHS statement on use of long-acting injectable ARTStudies on whether an oral lead-in is neededPresenter:Daniel R. Kuritzkes, MDChief, Division of Infectious DiseasesBrigham and Women’s HospitalHarriet Ryan Albee Professor of MedicineHarvard Medical SchoolBoston, MassachusettsFollow along with the slides at:https://bit.ly/3hNfHIISee the entire program at:https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Joseph J. Eron, Jr., MD, and Darcy Wooten, MD, share insights on HIV antiretroviral therapy safety and tolerability including recent data on weight gain and metabolic implications with INSTIs and NRTIs as well as the latest updates and recommendations on dolutegravir and pregnancy.Joseph J. Eron, Jr., MDProfessor of Medicine and EpidemiologyUniversity of North Carolina School of MedicineDirector, AIDS Clinical Trials UnitUniversity of North CarolinaChapel Hill, North CarolinaDarcy Wooten, MDAssociate Professor of MedicineDivision of Infectious Diseases and Global Public HealthDepartment of MedicineUniversity of California, San DiegoSan Diego, CaliforniaContent based on a CME program supported by independent educational grants from Janssen Therapeutics, Division of Janssen Products, LP, and ViiV HealthcareLink to full program:https://bit.ly/3ydMtcL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen to expert insights from Joseph J. Eron, Jr., MD, on exciting data about investigational agents (dapivirine ring, islatravir, lenacapavir, broadly neutralizing antibodies) for next-generation HIV prevention.Joseph J. Eron, Jr., MDProfessor of Medicine and EpidemiologyUniversity of North Carolina School of MedicineDirector, AIDS Clinical Trials UnitUniversity of North CarolinaChapel Hill, North CarolinaLink to full program:https://bit.ly/3ux6FF8 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode, Dr. Susan Buchbinder and Mr. Jontraye Davis discuss what has been learned and built through the past 40 years of HIV vaccine research, including how HIV vaccine scientific advancements and infrastructure were critical to the success of developing a COVID-19 vaccine.Presenters:Susan Buchbinder, MDClinical ProfessorDepartments of Medicine, Epidemiology and BiostatisticsUniversity of California, San FranciscoDirector, Bridge HIVSan Francisco Department of Public HealthSan Francisco, California Jontraye Davis, MHA, PMD ProCommunity Program Manager FHI 360Adjunct InstructorNorth Carolina Central UniversityDurham, North CarolinaSpecial Commentator: Jerome H. Kim, MDDirector GeneralInternational Vaccine InstituteSeoul, South KoreaLink to full series:https://bit.ly/3ytytMYLink to the HIV unmuted series from IAS:https://bit.ly/3f5qC0dContent is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, David A. Wohl, MD, discusses current guidelines and clinical trial data informing optimal selection of first-line antiretroviral therapy for HIV.David A. Wohl, MD Professor of MedicineSchool of MedicineSite Leader, AIDS Clinical Trials Unit-Chapel HillUniversity of North Carolina at Chapel HillDirector, North Carolina AIDS Training and Education CenterChapel Hill, North CarolinaCo-Director, HIV ServicesNorth Carolina Department of CorrectionRaleigh, North CarolinaLink to full program:https://bit.ly/3ux6FF8 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Roger Bedimo, MD, MS, FACP; Princy N. Kumar, MD, FIDSA, MACP; and Brian Wood, MD, answer healthcare professionals’ most pressing questions on caring for heavily treatment–experienced patients with HIV.Faculty:Roger Bedimo, MD, MS, FACP Professor of MedicineDivision of Infectious DiseasesUniversity of Texas Southwestern Medical CenterSection ChiefDivision of Infectious DiseasesDepartment of Internal MedicineVA North Texas Health Care SystemDallas, TexasPrincy N. Kumar, MD, FIDSA, MACPProfessor of Medicine and MicrobiologyChief, Division of Infectious Diseases and Tropical MedicineSenior Associate Dean of StudentsGeorgetown University School of MedicineWashington, DCBrian Wood, MDAssociate Professor of MedicineDivision of Allergy and Infectious DiseasesUniversity of WashingtonSeattle, WashingtonContent based on an online CME/CPE-certified program supported by educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3g8aBHs Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, the first in a yearlong series on Key Decisions in HIV Care, Daniel R. Kuritzkes, MD, and Chloe Orkin, MBChB, FRCP, MD, discuss important considerations when switching ART in patients with viral suppression on their current regimen, including guideline recommendations and data supporting different switch regimen options such as single-tablet triple therapy, 2-drug oral regimens, doravirine-based regimens, and long-acting injectable therapy. Following their dialogue, the faculty field questions from healthcare professionals.Presenters:Daniel R. Kuritzkes, MDChief, Division of Infectious DiseasesBrigham and Women's HospitalHarriet Ryan Albee Professor of MedicineHarvard Medical SchoolBoston, MassachusettsChloe Orkin, MBChB, FRCP, MDProfessor of HIV Queen Mary, University of LondonConsultant PhysicianLead for HIV ResearchBarts Health NHS TrustThe Royal London HospitalLondon, United KingdomContent based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Link to full program:https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen to expert insights from W. David Hardy, MD, on current options for pre-exposure prophylaxis and exciting new data on next-generation HIV prevention.W. David Hardy, MDScientific and Medical ConsultantAdjunct Clinical Professor of MedicineDivision of Infectious DiseasesKeck School of Medicine of USCLos Angeles, CaliforniaContent based on a CME program supported by an independent educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3ux6FF8 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this first episode, Dr. Linda-Gail Bekker and Ms. Maureen Luba discuss why an HIV vaccine remains the ultimate game-changer to ending the epidemic and the gaps it will address in the expanding HIV prevention landscape.Presenters:Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD Chief Operating Officer Desmond Tutu HIV Foundation Deputy DirectorDesmond Tutu HIV Centre Past PresidentInternational AIDS Society Faculty of Health Sciences University of Cape Town Cape Town, South AfricaMaureen LubaAfrica Region Advocacy AdvisorGlobal Advocacy for HIV PreventionAIDS Vaccine Advocacy CoalitionLink to full series:https://bit.ly/3ytytMYLink to the HIV unmuted series from IAS:https://bit.ly/3f5qC0dContent is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.